Vistagen Therapeutics (VTGN) Net Income (2016 - 2025)
Vistagen Therapeutics (VTGN) has disclosed Net Income for 14 consecutive years, with -$18.9 million as the latest value for Q4 2025.
- Quarterly Net Income fell 34.14% to -$18.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$67.0 million through Dec 2025, down 41.73% year-over-year, with the annual reading at -$51.4 million for FY2025, 75.12% down from the prior year.
- Net Income hit -$18.9 million in Q4 2025 for Vistagen Therapeutics, up from -$19.4 million in the prior quarter.
- In the past five years, Net Income ranged from a high of -$6.2 million in Q1 2021 to a low of -$19.8 million in Q2 2022.
- Historically, Net Income has averaged -$12.4 million across 5 years, with a median of -$12.5 million in 2021.
- Biggest five-year swings in Net Income: crashed 287.99% in 2021 and later surged 65.09% in 2023.
- Year by year, Net Income stood at -$10.5 million in 2021, then increased by 7.34% to -$9.8 million in 2022, then skyrocketed by 34.95% to -$6.4 million in 2023, then crashed by 121.87% to -$14.1 million in 2024, then plummeted by 34.14% to -$18.9 million in 2025.
- Business Quant data shows Net Income for VTGN at -$18.9 million in Q4 2025, -$19.4 million in Q3 2025, and -$15.1 million in Q2 2025.